Insiders who reported open-market trades in the last 12 months at the companies Eric E. Poma files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Allan Camaisa - $1K in CLDI purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Eric E. Poma is a corporate insider, tracked as Chief Executive Officer of Calidi Biotherapeutics, Inc. (CLDI). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Eric E. Poma submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Eric E. Poma been buying or selling stock?
Recorded transactions: 2 open-market purchases ($50K) and 0 open-market sales across all tracked filings.
Eric E. Poma is Chief Executive Officer of Calidi Biotherapeutics, Inc. (CLDI). 3 SEC Form 4 filings on record going back to 2025, most recently on 19 August 2026. Most recent open-market trade: bought $50K of CLDI on 26 August 2025. Lifetime open-market purchases: $50K.
Recent transactions
1
The latest SEC Form 4 transaction reported by Eric E. Poma.
InsiderAlpha's records for Eric E. Poma go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. The typical open-market purchase is $50K (1 of 2 buys carry a usable dollar value, totaling $50K). The largest single buy on record is $50K of CLDI in 2025. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
